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A Randomized Clinical Trial Comparing Ranibizumab and
Aﬂibercept (RIVAL Study)
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Purpose: To investigate differences in the development of macular atrophy (MA) over 24 months between
treat-and-extend (T&E) ranibizumab and aﬂibercept in patients with neovascular age-related macular degener-
ation (nAMD).
Design: A phase 4 randomized, partially masked, multicenter study.
Participants: Individuals 50 years of age or older diagnosed with active, treatment-naïve subfoveal choroidal
neovascularization secondary to nAMD with baseline best-corrected visual acuity (BCVA) of 23 logarithm of
minimum angle of resolution letters or more.
Methods: Patients were randomized 1:1 to receive either intravitreal injections of ranibizumab 0.5 mg or
aﬂibercept 2.0 mg and were treated according to the same reading centereguided T&E regimen after 3 initial
monthly injections.
Main Outcome Measures: The primary outcome was mean change in square root area of MA from baseline
to month 24. Key secondary outcomes included number of injections and mean change in BCVA from baseline to
months 12 and 24.
Results: Two hundred seventy-eight patients were included in the analysis (ranibizumab 0.5 mg, n ¼ 141;
aﬂibercept 2.0 mg, n ¼ 137). Mean change in square root area of MA from baseline to month 24 was þ0.36 mm
(95% conﬁdence interval [CI], 0.27e0.45 mm) for ranibizumab and þ0.28 mm (95% CI, 0.19e0.37 mm) for aﬂi-
bercept (treatment difference, þ0.08 mm [95% CI, 0.05 to 0.21 mm]; P ¼ 0.24). The proportion of patients with
MA increased from 7% (10/141) to 37% (43/117) for ranibizumab and from 6% (8/137) to 32% (35/108) for
aﬂibercept from baseline to month 24. The average number of injections received per year was similar between
both groups: 9.6 (95% CI, 9.2e10.0) for ranibizumab and 9.5 (95% CI, 9.1e9.9) for aﬂibercept. The mean change
in BCVA from baseline to month 24 was þ6.6 letters (95% CI,4.7e8.5 letters) for the ranibizumab group and þ4.6
letters (95% CI, 2.7e6.6 letters) for the aﬂibercept group ( P ¼ 0.15). Rates of adverse events (AEs) were similar
between both groups.
Conclusions: No signiﬁcant differences in the rate of development or growth of MA over 24 months were
observed between ranibizumab and aﬂibercept in nAMD patients treated using an identical T&E
regimen. Ophthalmology 2019;-:1e13 ª 2019 by the American Academy of Ophthalmology. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Supplemental material available at www.aaojournal.org.Antievascular endothelial growth factor (VEGF) inhibitors
such as ranibizumab and aﬂibercept are the mainstay of
therapy for patients with neovascular age-related macular
degeneration (nAMD).1 However, there is some concern
that long-term use of anti-VEGF agents may have an un-
desirable effect on the macula, possibly related to the role
that VEGF plays in maintaining the integrity of the retinal
pigment epithelium.2ª 2019 by the American Academy of Ophthalmology
This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/). Published by Elsevier Inc.Data on the development of macular atrophy (MA) in
patients receiving anti-VEGF therapy for nAMD are
conﬂicting. A number of studies have suggested a
relationship between anti-VEGF therapy and MA
development, particularly with more frequent treatment
regimens.3e11 In contrast, other studies have found no
statistically signiﬁcant association between the develop-
ment of MA and treatment with anti-VEGF agents,12,131https://doi.org/10.1016/j.ophtha.2019.08.023
ISSN 0161-6420/19
Figure 2. Flowchart showing patient disposition. MA ¼ macular atrophy.
Ophthalmology Volume -, Number -, Month 2019suggesting that MA may develop in these eyes as part
of the natural history of the underlying disease, rather
than its treatment. In addition, the current evidence for
involvement of anti-VEGF therapy in the development
of MA mainly is from studies of patients taking rani-
bizumab or bevacizumab, with very limited information
on those taking aﬂibercept.
The Development of Macular Atrophy in Patients with
Neovascular Age-Related Macular Degeneration: A Com-
parison of Ranibizumab and Aﬂibercept (RIVAL) study is a
prospective, randomized, head-to-head study to assess the
difference in the mean change in square root area of MA
from baseline to month 24 between ranibizumab and aﬂi-
bercept when these agents are administered via an identical
treat-and-extend (T&E) regimen. A 12-month interim
analysis of the RIVAL study results has been presented
elsewhere.14 The results of the full 24-month analysis are
described here.2Methods
The methods for the RIVAL study, which have been provided in
detail previously,14 are summarized here brieﬂy. The RIVAL study
was a 24-month, phase 4, randomized, partially masked, multicenter
study in patients with nAMD conducted at 24 sites across Australia
between April 2014 and November 2017. The study protocol was
reviewed and approved by an independent ethics committee for each
study site (detailed list of institutions provided in Appendix 1,
available at www.aaojournal.org). The RIVAL study was
conducted in accordance with International Conference on
Harmonization Good Clinical Practice guidelines and the tenets of
the Declaration of Helsinki. Written informed consent was
obtained from all patients. The study is registered at
clinicaltrials.gov (identiﬁer, NCT02130024).
Patients 50 years of age or older with baseline best-corrected
visual acuity (BCVA) of 23 logarithm of minimum angle of res-
olution (logMAR) letters or more (approximate Snellen equivalent,
20/400 þ 3) diagnosed with choroidal neovascularization affecting
the foveal center, secondary to nAMD in a treatment-naïve eye,
Table 1. Baseline Demographic Characteristics
Ranibizumab
0.5 mg
(n [ 142)
Aﬂibercept
2.0 mg
(n [ 139)
Age (yrs)*
Mean (SD) 76.6 (8.5) 78.7 (7.5)
Median 78 79
Gender, no. (%)
Male 70 (49.3) 63 (45.3)
Female 72 (50.7) 76 (54.7)
Family history (AMD), no. (%)
Yes 30 (21.1) 26 (18.7)
No 112 (78.9) 113 (81.3)
History of ATE, no. (%)
Yes 15 (10.6) 25 (18.0)
No 127 (89.4) 114 (82.0)
Ethnicity, no. (%)
White 132 (93.0) 130 (93.5)
Black 0 (0.0) 1 (0.7)
Asian 8 (5.6) 7 (5.0)
Other 2 (1.4) 1 (0.7)
Smoking history
Never smoked, no. (%) 67 (47.2) 67 (48.2)
Current smoker, no. (%) 12 (8.5) 10 (7.2)
Smoked in the past, no. (%) 63 (44.4) 62 (44.6)
Number of pack years, mean (SD) 34.4 (48.1) 26.0 (37.6)
AMD ¼ age-related macular degeneration; ATE ¼ arterial thromboem-
bolic event; SD ¼ standard deviation.
Randomized set.
*Age calculated at date of informed consent.
Gillies et al  Macular Atrophy in nAMDwithout restriction of lesion size or type, were included in the
study. Patients with 1 or more patches of MA that were more than
250 mm in the greatest linear dimension in either eye (measured
with multimodal imaging) were ineligible.15 Detailed inclusion and
exclusion criteria have been described previously.14
Patients were randomized 1:1 using a dynamic allocation
method in an interactive web-based response system (Medidata
Rave; Medidata Solutions, Inc, New York, NY) to receive either
ranibizumab 0.5 mg or aﬂibercept 2.0 mg according to a T&E
regimen for 24 months, as shown in Figure S1 (available at
www.aaojournal.org).
Patients were stratiﬁed at randomization by current treatment or
no current treatment for nAMD of the nonstudy fellow eye to
account for any potential contralateral effect of the medication on
the study eye. Randomization occurred within 3 strata: 2 treatment-
naïve eyes, 1 eye (ﬁrst or fellow nonstudy eye) being treated with
ranibizumab and 1 eye (ﬁrst or fellow nonstudy eye) being treated
with an anti-VEGF other than ranibizumab.
Patients in each group initially underwent 3 monthly loading
doses (baseline, week 4, and week 8). Subsequent treatment intervals
were determined according to the following disease activity criteria:
(1) loss of visual acuity (VA) of 5 letters or more than the best VA
recorded since treatment started (where VA loss was the result of
disease activity), (2) presence of new retinal hemorrhage (both
determined by the investigator), and (3) presence of intraretinal ﬂuid
(IRF) or subretinal ﬂuid (SRF) on spectral-domain OCT as deter-
mined by the masked central reading center (CRC). The CRC adju-
dicated the investigator’s assessment of disease activity based on
review of the images. The treatment interval was shortened by 2
weeks if 1 sign of activity was present andwas shortened to 4weeks if
2 or more signs of activity were present.14 Patients, but not
investigators, were masked to study treatment. Qualiﬁed personnelmasked to treatment allocation assessed BCVA scores at each
study site.
The primary end point of the study was the mean change in
square root area of MA from baseline to 24 months assessed by
the masked CRC using multimodal imaging. Macular atrophy was
deﬁned as loss of the retinal pigment epithelium, ellipsoid zone,
and external limiting membrane with concomitant subsiding of the
outer retinal layers together with increased signal transmission
below Bruch’s membrane of 100 mm or more in linear dimension
on OCT. On fundus autoﬂuorescence, an area of well-demarcated
hypoautoﬂuorescence of 100 mm or more in longest linear
dimension had to be present. Other causes of hypoauto-
ﬂuorescence such as blood or hard exudates had to be excluded
using color fundus photography and OCT. Macular atrophy was
deﬁned as a sharply demarcated area of partial or complete
depigmentation with visible underlying large choroidal vessels
100 mm or more in longest linear dimension on color fundus
photography. On ﬂuorescein angiography, well-demarcated areas
of window defects with sharply delineated hyperautoﬂuorescence
in the late phase of 100 mm or more in longest linear dimension
had to be present.
Key secondary efﬁcacy end points included the number of in-
jections from baseline to months 12 and 24 and the mean change in
BCVA using 4-m logMAR charts from baseline to months 12 and
24. Other secondary efﬁcacy end points included the proportion of
patients showing new MA over 12- and 24-month periods (detailed
list provided in Appendix 2, available at www.aaojournal.org).
Baseline measurements of MA were considered to be the last
available nonmissing MA area value collected just before the start
of treatment in the study eye, unless the baseline image was not
gradable, in which case, the protocol allowed the CRC to use either
the week 4 or week 8 image as the baseline image if a satisfactory
image was available at one of those time points.
Safety end points assessed included ocular and nonocular
adverse events (AEs) at all visits, retinal nerve ﬁber (RNF) analysis
(performed using the mean thickness of the RNF layer on a circle
scan of the optic nerve head using OCT at baseline and month 24)
and ocular inﬂammation at baseline and 7 days after injection after
the third mandated intravitreal injection.
Efﬁcacy assessments included visual and anatomic evaluations.
Macular atrophy was diagnosed by a multimodal approach using
color fundus photography, ﬂuorescein angiography, auto-
ﬂuorescence, and spectral-domain OCT. Macular atrophy diag-
nosis was conﬁrmed if it was present on 2 of these modalities, one
of which had to be either autoﬂuorescence or OCT imaging.
Best-corrected VA assessment was performed with a protocol
refraction by a trained refractionist masked to treatment allocation
using a logMAR chart at all visits. Other assessment details are
included in Appendix 3 (available at www.aaojournal.org).
The 24-month analysis was performed on the full analysis set,
which comprised all randomized patients who had at least 1
postbaseline efﬁcacy value for the primary end point. A random-
effects mixed model was used for the analysis of the primary
end point (with no imputation of missing data) to account for
correlations between repeated measures for both treatment groups,
with baseline area of MA as one of the covariates. The model
included change in area of MA (square root transformed data) from
baseline to months 12 and 24 as a response variable and included
continuous baseline area of MA (as graded by the CRC), treatment,
visit, and treatment by visit interaction as ﬁxed effect. Square root
transformation was used because this offsets the slower growth
rates with smaller lesions.16 The patient was modelled as a random
effect. The least square means and corresponding 95% conﬁdence
intervals (CIs) were estimated for each treatment group at months
12 and 24. The treatment differences, 95% CIs, and P values also
were estimated at months 12 and 24.3
Table 2. Baseline* Ocular Characteristics
Ranibizumab
0.5 mg
(n [ 142)
Aﬂibercept
2.0 mg
(n [ 139)
Mean BCVA (logMAR letters)
No. 142 139
Mean (SD) 65.0 (15.4) 65.2 (12.6)
Approximate Snellen
equivalent
20/50 20/50
Median 68 67
CNV location on FA,
no. (%)
No. 141 139
Subfoveal 129 (92) 113 (81)
Juxtafoveal 9 (6) 20 (14)
Extrafoveal 3 (2) 5 (4)
N/A e 1 (1)
CNV type on FA, no. (%)
No. 141 139
Predominantly classic 21 (15) 27 (19)
Minimally classic/occult 119 (84) 111 (80)
Other 1 (1) 0 (0.0)
N/A e 1 (1)
Area of lesion on
FA (mm2)
No. 141 138
Mean (SD) 6.0 (4.8) 6.0 (4.6)
Median 4.8 5.3
Area of active CNV
on FA (mm2)
Total no. 140 138
Mean (SD) 5.2 (4.1) 5.1 (3.9)
Median 4.2 4.4
Hemorrhage on CFP,
no. (%)
No. 140 138
Yes 62 (44) 52 (38)
No 78 (55) 86 (62)
N/A 1 (1) e
CSFT (mm)
No. 141 139
Mean (SD) 468 (151) 483 (168)
Median 423 451
IRF status, no. (%)
No. 141 139
Absent 72 (51) 76 (55)
Present 69 (49) 63 (45)
SRF status, no. (%)
No. 141 139
Absent 15 (11) 17 (12)
Present 126 (89) 122 (88)
SHRM status, no. (%)
No. 141 139
Absent 23 (16) 38 (27)
Present 118 (84) 101 (73)
PED status, no. (%)
No. 141 139
Absent 4 (3) 3 (2)
Present 137 (97) 136 (98)
PED type, no. (%)
No. 141 139
Solid 17 (12) 17 (12)
Hollow 24 (17) 27 (19)
Mixed 96 (68) 92 (66)
N/A 4 (3) 3 (2)
Table 2. (Continued.)
Ranibizumab
0.5 mg
(n [ 142)
Aﬂibercept
2.0 mg
(n [ 139)
Subfoveal choroidal
thickness (mm)
No. 138 134
Mean (SD) 194 (78) 190 (82)
Median 191 172
Overall diagnosis of MA, no. (%)
No. 141 139
Yes 10 (7) 9 (6)
No 131 (93) 130 (94)
Area of atrophy (mm2)
No. 140 139
Mean (SD) 0.01 (0.05) 0.06 (0.35)
Median 0.000 0.000
Minimum 0.00 0.00
Maximum 0.44 3.69
Longest linear dimension (mm)
No. 138 135
Mean (SD) 19.6 (82) 30.2 (193)
Median 0.0 0.0
Minimum 0 0
Maximum 518 1794
Atrophy location, no. (%)
Central subﬁeld
No. 141 139
Yes 1 (1) 1 (1)
No 8 (6) 8 (6)
N/A 132 (93) 130 (93)
Inner subﬁeld, no. (%)
No. 141 139
Yes 7 (5) 9 (6)
No 2 (1) 0 (0)
N/A 132 (94) 130 (94)
Outer subﬁeld, no. (%)
No. 141 139
Yes 1 (1) 3 (2)
No 8 (6) 6 (4)
N/A 132 (93) 130 (94)
AF ¼ autoﬂuorescence; BCVA ¼ best-corrected visual acuity;
CNV ¼ choroidal neovascularization; CFP ¼ color fundus photography;
CSFT ¼ central subﬁeld foveal thickness; FA ¼ ﬂuorescence angiography;
IRF ¼ intraretinal ﬂuid; logMAR ¼ logarithm of minimum angle of res-
olution; MA ¼ macular atrophy; N/A ¼ not available; PED ¼ pigment
epithelial detachment; SRF ¼ subretinal ﬂuid; SHRM ¼ subretinal
hyperreﬂective material; SD ¼ standard deviation.
Randomized set.
*Last available nonmissing value collected just before the start of treatment
in the study eye.
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4A supporting analysis of the primary end point also was carried
out on the per-protocol set using the same random-effects mixed
model. The per-protocol set consisted of all patients in the full
analysis set who followed the treatment regimen as randomized
and completed the study without clinically signiﬁcant protocol
deviations. Sensitivity analyses were carried out by ﬁtting the
mixed model with missing data imputed using the last observation
carried forward imputation method.
The proportion of patients with new MA at months 12 and 24
was analyzed using a logistic regression model, and the number of
Figure 3. Bar graph showing the mean change in square root area of macular atrophy (MA) from baseline, full analysis set. Least square means are the
estimated change in area of MA from baseline; mixed-model analysis adjusting for baseline area of MA (primary analysis); mixed model: change from
baseline (square root MA area [mm]) ¼ baseline (square root MA area) þ treatment þ visit þ treatment  visit þ subject (random effect); treatment
difference: ranibizumab  aﬂibercept; MA area is treated as 0 if MA is reported as absent (overall determination of MA presence). CI ¼ conﬁdence interval.
Gillies et al  Macular Atrophy in nAMDinjections from baseline to months 12 and 24 was analyzed using a
negative binomial regression model. The analysis of the change in
BCVA from baseline was conducted using a similar random-
effects mixed model as for the primary end point, with contin-
uous baseline BCVA as one of the covariates. Further details of the
statistical methods, including sample size calculations, are pro-
vided in Appendix 4 (available at www.aaojournal.org).
Results
Patient Disposition
Overall, 314 patients were screened and 281 were randomized
(ranibizumab, n ¼ 142; aﬂibercept, n ¼ 139). A total of 56 pa-
tients (19.9%) discontinued from the study. The proportion was
similar between treatment groups: (ranibizumab, 25 [17.6%];
aﬂibercept, 31 [22.3%]); the most frequent reasons for discon-
tinuation in the ranibizumab and aﬂibercept groups were AEs and
the patient’s decision to withdraw consent, respectively (Fig 2).
Two hundred seventy-eight patients (98.9%) were included in
the full analysis set (ranibizumab, n ¼ 141 [99.3%];
aﬂibercept, n ¼ 137 [98.6%]).
Demographics and Baseline Characteristics
Demographics and baseline characteristics were comparable
between the treatment groups (Table 1). Patients in the
ranibizumab group had a mean age of 76.6 years (standard
deviation [SD], 8.5 years), and 51% were women; those in the
aﬂibercept group had a mean age of 78.7 years (SD, 7.5
years), and 55% were women. Most patients were treatment-
naïve in both eyes (83.1% for ranibizumab and 87.1% for
aﬂibercept). The mean total BCVA scores in the randomized
set were 65.0 logMAR (SD, 15.4 logMAR; approximate
Snellen equivalent, 20/50) and 65.2 logMAR (SD, 12.6
logMAR; approximate Snellen equivalent, 20/50) in the
ranibizumab and aﬂibercept groups, respectively. Most patients
showed minimally classic or occult choroidalneovascularization type at baseline in both treatment groups
(Table 2).
Efﬁcacy Analyses
Macular Atrophy. Themean square root area ofMA increased from
0.02 mm (SD, 0.10 mm; n ¼ 140) at baseline to 0.19 mm (SD, 0.45
mm; n¼ 126) at 12 months and 0.40 mm (SD, 0.73 mm; n¼ 114) at
24 months in the group receiving ranibizumab, whereas it increased
from 0.05 mm (SD, 0.23 mm; n¼ 137) at baseline to 0.20 mm (SD,
0.44; n¼ 120) at 12months and 0.35mm (SD, 0.65mm; n¼ 106) at
24 months in the group receiving aﬂibercept.
The primary mixed-model analysis estimated the mean change
in square root area of MA from baseline at month 12 to be þ0.16
mm (95% CI, 0.07e0.25 mm) for ranibizumab and þ0.14 mm
(95% CI, 0.05e0.23 mm) for aﬂibercept, a treatment difference
of þ0.02 mm (95% CI, 0.11 to 0.15 mm; P ¼ 0.77) and þ0.36
mm (95% CI, 0.27e0.45 mm) for ranibizumab and þ0.28 mm
(95% CI, 0.19e0.37 mm) for aﬂibercept at month 24, a treatment
difference of þ0.08 mm (95% CI, 0.05 to 0.21 mm; P ¼ 0.24;
Fig 3).
Results from the per-protocol analysis were consistent with those
of the primary analysis. The mean change in square root area of MA
from baseline at month 12 wasþ0.18 mm (95% CI, 0.08e0.28 mm)
for ranibizumab and þ0.15 mm (95% CI, 0.04e0.26 mm) for
aﬂibercept; a treatment difference of 0.03 mm (95% CI, 0.12 to
0.18 mm; P ¼ 0.68), and þ0.40 mm (95% CI, 0.30e0.50 mm) for
ranibizumab and þ0.32 mm (95% CI, 0.21e0.43 mm) for aﬂi-
bercept at month 24; a treatment difference of 0.08 mm (95%
CI, 0.07 to 0.24 mm; P ¼ 0.27), as shown in Figure 4A.
The results of a sensitivity analysis for the square root trans-
formed area of MA using data imputation following the last
observation carried forward method for eyes that dropped out was
consistent with those of the primary analysis. The mean change in
square root area of MA from baseline at month 12 was þ0.14 mm
(95% CI, 0.06e0.23 mm) for ranibizumab and þ0.14 mm (95%
CI, 0.06e0.22 mm) for aﬂibercept; a treatment difference of 0.00
mm (95% CI, 0.12 to 0.12 mm; P ¼ 0.97); and þ0.30 mm (95%
CI, 0.22e0.38 mm) for ranibizumab and þ0.24 mm (95% CI,5
Figure 4. A, Bar graph showing the mean change in square root area of macular atrophy (MA) from baseline (per-protocol analysis). Mixed model: change
from baseline (square root MA area [mm]) ¼ baseline (square root MA area) þ treatment þ visit þ treatment  visit þ subject (random effect); least square
means are the estimated changes in area of MA from baseline. CI ¼ conﬁdence interval; n ¼ number of patients. B, Bar graph showing the mean change in
square root area of macular atrophy from baseline (sensitivity analysis), full analysis set. Mixed model: change from baseline (square root MA area [mm]) ¼
baseline (square root MA area) þ treatment þ visit þ treatment  visit þ subject (random effect); least square means are the estimated changes in area of
MA from baseline. CI ¼ conﬁdence interval.
Ophthalmology Volume -, Number -, Month 20190.16e0.32 mm) for aﬂibercept at month 24; a treatment difference
of 0.06 mm (95% CI, 0.06 to 0.18 mm; P ¼ 0.31), as shown in
Figure 4B.
The proportion of patients with MA increased from
7% (10/141) at baseline to 24% (31/127) and 37% (43/117) at
months 12 and 24 for ranibizumab and from 6% (8/137) to
26% (31/121) and 32% (35/108) for aﬂibercept (Fig 5). A
logistic regression analysis estimated that patients in the
ranibizumab group had a 19% higher chance (odds ratio
[OR], 1.19; 95% CI, 0.67e2.09) of new MA developing
than the aﬂibercept group. However, this difference was not
statistically signiﬁcant (P ¼ 0.55; Fig 6).
Number of Injections. The mean number of intravitreal in-
jections from baseline to month 12 was similar for the ranibizumab6(9.7 injections [SD,2.8 injections]) and aﬂibercept (9.7 injections [SD,
2.5 injections]) groups. The mean number of injections administered
betweenmonths 12 and 24 was similar between both groups, with 8.9
injections (SD, 3.2 injections) in the ranibizumab group and 8.3 in-
jections (SD, 3.6 injections) in the aﬂibercept group. Over the entire
24-month study period, the mean number of injections was 17.7 in-
jections (SD, 6.4 injections) in the ranibizumab group and 17.0 in-
jections (SD, 6.3 injections) in the aﬂibercept group (Fig 7).
A negative binomial regression model applied to the 24-month
study period estimated that the average number of injections received
per year was similar between the groups: 9.6 injections (95%
CI, 9.2e10.0 injections) for ranibizumab and 9.5 injections (95%
CI, 9.1e9.9 injections) for aﬂibercept, with an injection rate ratio
for ranibizumab to aﬂibercept of 1.01 (95%CI, 0.95e1.08;P¼ 0.75).
Figure 5. Graph showing the proportion of patients with macular atrophy (MA) at months 12 and 24, full analysis set. A diagnosis of MA was conﬁrmed if
it was present in 2 of the imaging methods, 1 of which had to be OCT or autoﬂuorescence. Baseline measurements of MA were considered to be the last
available nonmissing MA area value collected just before the start of treatment in the study eye, unless the baseline image was not gradable, in which case
the protocol allowed the central reading center to use either the week 4 or week 8 image as the baseline image if a satisfactory image was available at one of
those time points.
Gillies et al  Macular Atrophy in nAMDSimilar proportions of patients in the ranibizumab and aﬂi-
bercept groups achieved a maximum interval of 12 weeks (32%
and 31%, respectively), 8 weeks (20% and 19%, respectively), or 6
weeks (20% and 23%, respectively) at least once during the study,
as shown in Figure S8 (available at www.aaojournal.org). Eighty-
six patients (64%) from the ranibizumab group and 79 patients
(59%) from the aﬂibercept group returned to monthly injections
at least once.Figure 6. Bar graph showing the proportion of patients with newly developed m
regression analysis includes early withdrawal data. Baseline measurements of
collected just before the start of treatment in the study eye, unless the baselin
reading center to use either the week 4 or week 8 image as the baseline image i
month 12¼ patients with no MA at baseline who demonstrated new MA (deﬁne
month 24¼ patients with no MA at month 12 who demonstrated new MA (deﬁ
month 24 ¼ patients with no MA at baseline who demonstrated new MA (deﬁ
ratio for treatment difference is ranibizumab versus aﬂibercept comparing odd
regression model included treatment as factor. Model: log(p / 1 e p) ¼ treatmeBest-Corrected Visual Acuity. Similar mean BCVA gains
were observed between ranibizumab and aﬂibercept at Months 12
and 24. The mean BCVA at baseline was 65.3 letters (SD, 15.1
letters; approximate Snellen equivalent 20/50) and 65.1 letters (SD,
12.5 letters; approximate Snellen equivalent, 20/50) in the ranibi-
zumab (n ¼ 141) and aﬂibercept (n ¼ 137) treatment groups,
respectively. The mean change in BCVA was þ6.9 letters (SD,
12.3 letters) for the ranibizumab group and þ5.2 letters (SD, 12.8acular atrophy (MA) from baseline to month 24, full analysis set. Logistic
MA were considered to be the last available nonmissing MA area value
e image was not gradable, in which case the protocol allowed the central
f a satisfactory image was available at one of those time points. Baseline to
d as diagnosis of MA change from “no” to “yes”) by month 12. Month 12 to
ned as diagnosis of MA change from “no” to “yes”) by month 24. Baseline to
ned as diagnosis of MA change from “no” to “yes”) by month 24. The odds
s of newly developed MA (yes) at the speciﬁed study visit. The logistic
nt. Each visit was analyzed by a separate model. CI ¼ conﬁdence interval.
7
Figure 7. Bar graph showing the mean number of injections at months 12 and 24, full analysis set. At month 24, n ¼ 127 for the ranibizumab group and n¼
121 for the aﬂibercept group. The month 12 injection count was included in the second year of treatment. The period cutoff was based on nominal visit
window. Injections per year are the total number of injections divided by the total exposure in years. Exposure is the follow-up duration in the speciﬁed
period. SD ¼ standard deviation.
Ophthalmology Volume -, Number -, Month 2019letters) for the aﬂibercept group at month 12 and was þ6.5 letters
(SD, 14.4 letters) for the ranibizumab group and þ5.3 letters (SD,
13.3 letters) for the aﬂibercept group at month 24 (Fig 9).
The mixed model (adjusting for baseline BCVA) estimated
the mean change in BCVA from baseline to month 12 to be þ7.2
letters (95% CI, 5.3e9.0 letters) for the ranibizumab group
and þ4.8 letters (95% CI, 3.0e6.7 letters) for the aﬂibercept
group; the treatment difference was 2.3 letters (95% CI, 0.3 to
4.9 letters; P ¼ 0.08). At month 24, the mean change in BCVA
was estimated to be þ6.6 letters (95% CI, 4.7e8.5 letters) for the
ranibizumab group and þ4.6 letters (95% CI, 2.7e6.6 letters) forFigure 9. Graph showing the mean change in best-corrected visual acuity (BCV
window from the case report form, that is, ﬁxed visits included baseline, week 4,
value collected just before the start of treatment in the study eye. logMAR ¼
8the aﬂibercept group, with a treatment difference of 2.0 letters
(95% CI, 0.7 to 4.6 letters; P ¼ 0.15), as shown in Table S3
(available at www.aaojournal.org). The results of the sensitivity
analysis were consistent with those of the primary analysis, as
described in Appendix 4 (available at www.aaojournal.org).
A gain of 15 letters or more from baseline in BCVA was
achieved by 22% of patients (28/127) at month 12 in the ranibi-
zumab group, compared with 21% of patients (25/121) in the
aﬂibercept group. A gain of 15 letters or more from baseline in
BCVA was achieved by 25% of patients (29/117) at month 24 in
the ranibizumab group, compared with 19% of patients (20/108) inA) at months 12 and 24, full analysis set. Observed data at the nominal visit
week 8, month 12, and month 24. Baseline is the last available nonmissing
logarithm of minimum angle of resolution.
Table 4. Most Frequent Ocular (2 Patients in Any Group)
Adverse Events, Regardless of Causal Relationship, by
Preferred Term
Preferred Term*
Ranibizumab
0.5 mg (n [ 141)
Aﬂibercept
2.0 mg (n [ 139)
Ocular AEs, total 101 (71.6) 115 (82.7)
Eye pain 24 (17) 24 (17.3)
Vitreous ﬂoaters 18 (12.8) 17 (12.2)
Age-related macular
degeneration
16 (11.3) 19 (13.7)
Dry eye 14 (9.9) 14 (10.1)
Cataract operation 12 (8.5) 16 (11.5)
Lacrimation increased 11 (7.8) 11 (7.9)
Cataract 8 (5.7) 22 (15.8)
Choroidal neovascularization 8 (5.7) 8 (5.8)
Eye irritation 8 (5.7) 9 (6.5)
Vision blurred 8 (5.7) 11 (7.9)
Visual acuity reduced 8 (5.7) 5 (3.6)
Vitreous detachment 8 (5.7) 20 (14.4)
Ocular hyperemia 7 (5.0) 11 (7.9)
Retinal hemorrhage 7 (5.0) 7 (5.0)
Conjunctival hemorrhage 6 (4.3) 4 (2.9)
Retinal pigment epithelial tear 6 (4.3) 4 (2.9)
Eye discharge 5 (3.5) 6 (4.3)
Corneal abrasion 4 (2.8) 4 (2.9)
Posterior capsule opaciﬁcation 4 (2.8) 5 (3.6)
Asthenopia 3 (2.1) 2 (1.4)
Blepharitis 3 (2.1) 4 (2.9)
Conjunctivitis 3 (2.1) 3 (2.2)
Drug hypersensitivity 3 (2.1) 3 (2.2)
Eye pruritus 3 (2.1) 7 (5.0)
Eye swelling 3 (2.1) 2 (1.4)
Eyelid ptosis 3 (2.1) 0 (0.0)
Foreign body sensation 3 (2.1) 4 (2.9)
Intraocular lens implant 3 (2.1) 4 (2.9)
Intraocular pressure increase 3 (2.1) 3 (2.2)
Photopsia 3 (2.1) 3 (2.2)
Posterior lens capsulotomy 3 (2.1) 1 (0.7)
Punctate keratitis 3 (2.1) 1 (0.7)
Chalazion 2 (1.4) 7 (5.0)
Macular ﬁbrosis 2 (1.4) 3 (2.2)
Metamorphopsia 2 (1.4) 7 (5.0)
Visual impairment 2 (1.4) 5 (3.6)
Detachment of retinal
pigment epithelium
1 (0.7) 3 (2.2)
Diplopia 1 (0.7) 4 (2.9)
Glaucoma 1 (0.7) 3 (2.2)
Pain N/A 3 (2.2)
AE ¼ adverse event; N/A ¼ not available.
Safety set. Data are no. (%). Percentages are based on the number of pa-
tients in each group. Events are arranged by decreasing order of incidence
in the ranibizumab group. Treatment-emergent adverse events are included
and are considered by the onset date on or after the date of ﬁrst study
treatment.
*According to the Medical Dictionary for Regulatory Activities,
version 17.
Gillies et al  Macular Atrophy in nAMDthe aﬂibercept group, as seen in Figure S10A (available at
www.aaojournal.org). A logistic regression model estimated the
odds of a 15-letter or more gain from baseline at month 12 and
month 24 to be 5% and 61% higher with ranibizumab versus
aﬂibercept (month 12: OR, 1.05 [95% CI, 0.53e2.08; P ¼ 0.89];
month 24: OR, 1.61 [95% CI, 0.77e3.35; P ¼ 0.21]; Fig S10A
[available at www.aaojournal.org]).At month 12, 97% of patients (123/127) showed a 15-letter or
fewer loss from baseline in BCVA in the ranibizumab group
compared with 95.0% of patients (115/121) in the aﬂibercept
group. At month 24, 94% of patients (110/117) showed a 15-letter
or fewer loss from baseline in BCVA in the ranibizumab group
compared with 94% of patients (102/108) in the aﬂibercept group,
as shown in Figure S10B (available at www.aaojournal.org).
A logistic regression model estimated the odds of a 15-letter or
fewer loss from baseline at month 12 to be 63% higher with
ranibizumab versus aﬂibercept (OR, 1.63 [95% CI, 0.45e5.93];
P ¼ 0.46). Patients in the ranibizumab group showed a similar
chance (OR, 0.94 [95% CI, 0.30e2.90]; P ¼ 0.91) as the aﬂi-
bercept group to have a 15-letter of fewer loss from baseline in
BCVA at month 24, as shown in Figure S10B (available at
www.aaojournal.org).
Central Subﬁeld Foveal Thickness. The mean central subﬁeld
foveal thickness (CSFT) at baseline was 468 mm (SD, 151 mm) and
484 mm (SD, 168 mm) in the ranibizumab and aﬂibercept groups,
respectively. The mean CSFT decreased to 314 mm (SD, 85 mm; n¼
127) at month 12, with a mean change from baseline of 147 mm
(SD, 128 mm), in the ranibizumab group and to 308 mm (91 mm; n¼
120), with a mean change in baseline of 172 mm (SD, 150 mm), in
the aﬂibercept group. The mean CSFT decreased further at month
24 to 306 mm (SD, 81 mm; n ¼ 117), with a mean change from
baseline of151 mm (SD, 133 mm), in the ranibizumab group and to
299 mm (SD, 78 mm; n ¼ 108), with a mean change from baseline
of 182 mm (SD, 156 mm), in the aﬂibercept group.
The mixed-model analysis (adjusting for baseline CSFT) esti-
mated the mean change in CSFT from baseline at month 12 to
be 153 mm (95% CI, 167 to 140 mm) for the ranibizumab
group and 163 mm (95% CI, 177 to 150 mm) for the aﬂi-
bercept group, with a treatment difference of 10.1 mm (95%
CI, 8.8 to 29 mm; P ¼ 0.29). At month 24, the mean change in
CSFT was estimated to be 161 mm (95% CI, 174 to e147 mm)
for the ranibizumab group and 173 mm (95% CI, 186 to 159
mm) for the aﬂibercept group, with a treatment difference of 11.9
mm (95% CI, 7.4 to 31 mm; P ¼ 0.23).
Intraretinal Fluid and Subretinal Fluid. Approximately 4% of
patients in each group showed no IRF or SRF at baseline. This
increased to 57% in the ranibizumab group and 61% in the aﬂi-
bercept group at month 2. The proportion of patients with no SRF
or IRF at months 12 and 24 appeared to be stable at 56% and 57%
in the ranibizumab group and 64% and 61% in the aﬂibercept
group, respectively, as shown in Figure S11 (available at
www.aaojournal.org).
Plasma Vascular Endothelial Growth Factor Levels. The
mean concentration of plasma VEGF at baseline was 44 pg/ml
(SD, 43 pg/ml) in the ranibizumab group (n ¼ 139) and 42 pg/ml
(SD, 35 pg/ml) in the aﬂibercept group (n ¼ 137). The mean
changes in plasma concentrations of VEGF from baseline at weeks
5 and 9 (7 days after the second and third intravitreal injections,
respectively) were 0.5 pg/ml and þ0.5 pg/ml, respectively, in the
ranibizumab group and 26 pg/ml and 25 pg/ml, respectively, in
the aﬂibercept group.
A random-effects mixed model adjusting for baseline plasma
VEGF concentrations found a statistically signiﬁcant difference
between ranibizumab and aﬂibercept in the estimated change in
plasma VEGF concentration from baseline at both week 5 and
week 9 (both P < 0.001), as shown in Figure S12 (available at
www.aaojournal.org). The least square means change at week 5
was þ0.30 pg/ml (95% CI, 3.8 to 4.4 pg/ml) and 26.9 pg/ml
(95% CI, 31 to 23 pg/ml) in the ranibizumab and aﬂibercept
groups, respectively. At week 9, the change was þ1.6 pg/ml
(95% CI, 2.5 to 5.8 pg/ml) and e27.3 pg/ml (95% CI, 31
to 23 pg/ml) in the ranibizumab and aﬂibercept groups,
respectively.9
Table 5. Deaths and Serious Adverse Events
Preferred Term*
Ranibizumab
0.5 mg
(n [ 141)
Aﬂibercept
2.0 mg
(n [ 139)
Deaths, totaly 3 (2.1) 6 (4.3)
Ocular SAEs, total 2 (1.4) 4 (2.9)
Ocular SAEs (1 patient in any group)
Cataract traumatic 1 (0.7) 0 (0.0)
Retinal artery embolism 1 (0.7) 0 (0.0)
Retinal artery occlusion 1 (0.7) 0 (0.0)
Retinal detachment 0 (0.0) 2 (1.4)
Endophthalmitis 0 (0.0) 2 (1.4)
Nonocular SAEs, total 50 (35.5) 54 (38.8)
Nonocular SAEs (2% in any group)
Atrial ﬁbrillation 7 (5.0) 0 (0.0)
Basal cell carcinoma 7 (5.0) 2 (1.4)
Pneumonia 4 (2.8) 4 (2.9)
Squamous cell carcinoma 4 (2.8) 4 (2.9)
Aphasia 3 (2.1) 0 (0.0)
Chest pain 3 (2.1) 2 (1.4)
Fall 3 (2.1) 1 (0.7)
Femoral neck fracture 3 (2.1) 2 (1.4)
Renal failure acute 3 (2.1) 2 (1.4)
Syncope 3 (2.1) 2 (1.4)
Urinary tract infection 2 (1.4) 4 (2.9)
Cerebrovascular accident 1 (0.7) 3 (2.2)
SAE ¼ serious adverse event.
Safety set. Data are no. (%). Percentages are based on the number of pa-
tients in each group. Events are arranged by decreasing order of incidence
in the ranibizumab group. Treatment-emergent adverse events are included
and are considered by the onset date on or after the date of ﬁrst study
treatment.
*According to the Medical Dictionary for Regulatory Activities,
version 17.
yThree in the ranibizumab group (cardiac failure, femoral neck fracture, and
metastatic esophageal cancer, n ¼ 1 each) and 6 in the aﬂibercept group
(acute renal failure, adrenal gland cancer, angioimmunoblastic T-cell
lymphoma, cardiac failure, malignant neoplasm progression with obstruc-
tive uropathy, metabolic acidosis, n ¼ 1 each).
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Overall, 255 patients (91.1%) experienced at least 1 AE during the
study (125 patients [88.7%] in the ranibizumab group and 130
patients [93.5%] in the aﬂibercept group). Eye pain was the most
commonly reported ocular AE in both groups (Table 4). At least 1
nonocular serious AE during the study was reported by 50 patients
(35.5%) in the ranibizumab group and 54 patients (38.8%) in the
aﬂibercept group (Table 5). Nine patients (6%) in the
ranibizumab group and 14 patients (10%) in the aﬂibercept
group discontinued the study because of an AE, and 7 patients
(5%) in the ranibizumab group and 14 patients (10%) in the
aﬂibercept group discontinued the study because of a serious AE.
A total of 9 deaths were reported; none was suspected by the
investigator to be related to treatment (Table 5).
Arterial thromboembolic events were distributed similarly
between the groups: 11 patients (8%) in the ranibizumab group
and 7 patients (5%) in the aﬂibercept group, as shown in Table S6
(available at www.aaojournal.org). The proportion of patients who
experienced a reduction in RNF thickness was similar between
both groups at month 12 (3/122 [2.5%] in the ranibizumab
group and 3/111 [2.7%] in the aﬂibercept group). These
proportions were 3.6% in the ranibizumab group (4/110 patients)
and 1% in the aﬂibercept group (1/97 patients) at month 24, as10shown in Table S7 (available at www.aaojournal.org).
Approximately 5% of ranibizumab patients and 7% of
aﬂibercept patients demonstrated grade 1þ anterior chamber
cells by week 9, and approximately 6% of ranibizumab and
7% of aﬂibercept patients demonstrated grade 1 anterior
chamber ﬂare by week 9.
Discussion
The RIVAL study is a prospective randomized study to
compare ranibizumab and aﬂibercept using a CRC-
controlled T&E regimen. The square root area of MA
increased from baseline to month 24 in both groups (rani-
bizumab, 0.36 mm; aﬂibercept, 0.28 mm), but there was no
statistically signiﬁcant difference between the 2 groups. The
proportion of patients with new MA at 12 and 24 months
was comparable between the 2 treatment groups. The
change in square root area of MA at month 12 was similar to
that found in earlier natural history studies, including the
Age-Related Eye Disease Study 2.17,18 Natural history
studies of MA over a duration of 4 years and more have
reported a growth rate in MA of 1.5 to 2.2 mm2/year, which
may indicate faster growth than in our study.19 The
development of new MA results in our study were
consistent with those described in the post hoc analysis of
the Phase III, Double-Masked, Multicenter, Randomized,
Active Treatment-Controlled Study of the Efﬁcacy and
Safety of 0.5 mg and 2.0 mg Ranibizumab Administered
Monthly or on an As-Needed Basis (Pro Re Nata [PRN]) in
Patients with Subfoveal Neovascular Age-Related Macular
Degeneration.20 The Inhibition of VEGF in Age-Related
Choroidal Neovascularization study also found no signiﬁ-
cant difference in the proportion of patients demonstrating
MA with both continuous (monthly) and discontinuous
regimens of 2 anti-VEGF agents (ranibizumab and bev-
acizumab).6 Data on the development of MA in patients
taking aﬂibercept are limited. Kuroda et al11 reported that
MA developed in 10% of eyes during 1 year of aﬂibercept
treatment.
Some differences in injection rates were evident between
the present study and others that used variable treatment
regimens. The similar mean number of injections in the ﬁrst
year (approximately 10) between the ranibizumab and aﬂi-
bercept groups is higher than that observed in many previ-
ous studies, although injection rates were similar for both
the ﬁrst and the second year to the T&E arm of the Treat-
and-Extend Protocol in Patients with Wet Age-Related
Macular Degeneration study.18,21e23 The Fight Retinal
Blindness! registry analysis of 2-year outcomes using T&E
in a real-world setting reported a lower number of injections
(14.2 injections) over 2 years than the RIVAL study.24,25
One of the differences with other studies is that in the
RIVAL study, the investigator assessments of ﬂuid on OCT
were adjudicated by a masked CRC that made the ﬁnal
treatment interval decision, unlike most other studies in
which ﬂuid assessments usually were made solely by
investigators.
Approximately 60% of patients in our study needed to
return to monthly injections at some point, twice on average,
over 24 months in both groups. Approximately 30% of
Gillies et al  Macular Atrophy in nAMDpatients in each group achieved a maximum treatment
interval of 12 weeks at least once during the study, with
maximum intervals of 6 and 8 weeks being the next most
common (20% of patients in each group). Evidence also
suggests that a T&E regimen can result in better outcomes
than a pro re nata regimen.12,25
No differences were found in BCVA gains between the
treatment groups, and the mean changes in BCVA in the
RIVAL study were similar to those of previous
studies.3,12,24,26 The mean BCVA after 2 years was more
than 70 letters in both groups, despite a high mean BCVA at
baseline, which has been associated with lower mean visual
improvements because of a ceiling effect whereby gains are
limited by an upper threshold above which patients cannot
improve. The good visual gains achieved despite the high
baseline BCVA may be related to the high treatment fre-
quency or to the restrictions on the presence and size of MA
in either eye at baseline in our study.
The mean reduction in CSFT in the RIVAL study also
was similar to that of earlier studies,3,12,26,27 but the pro-
portion of patients with a dry retina after 24 months in both
groups was higher than that reported in the VEGF Trap-Eye:
Investigation of Efﬁcacy and Safety in Wet Age-Related
Macular Degeneration study and the Inhibition of VEGF
in Age-Related Choroidal Neovascularization study.3,6,26 It
is possible that further analysis of the current study’s data
could provide interesting insights into the association be-
tween a dry retina and good VA results. In fact, the 24-
month results from the A Phase IV, Randomized,
Controlled, Single Masked Study Investigating the Efﬁcacy
and Safety of Ranibizumab “Inject and Extend” Using an
Intensive Retinal Fluid Retreatment Regimen Compared to a
Relaxed Retinal Fluid Retreatment Regimen in Patients with
Wet Age-Related Macular Degeneration study reported that
patients treated with a ranibizumab T&E regimen that
allows some SRF (200 mm) achieved similar visual out-
comes as a regimen that did not tolerate any SRF, with
signiﬁcantly fewer ranibizumab injections.28 Although it is
difﬁcult to infer anything from the 2 nonsigniﬁcant trends,
the tendency of aﬂibercept to dry the retina more and
result in less atrophy seems inconsistent with the concern
that more drying causes more atrophy.
The difference in change in plasma VEGF concentration
between treatment groups was statistically signiﬁcant
(P < 0.001) at weeks 5 and 9, that is, 7 days after the second
and third injections. These results are aligned with previous
studies that show that aﬂibercept therapy results in greater,
more sustained reduction in systemic VEGF levels than
ranibizumab, as may be expected based on the structural
differences between the 2 molecules.29e31 However,
reduced systemic VEGF levels in the patients receiving
aﬂibercept did not seem to be associated with an increased
risk of arterial thromboembolic events.
Other safety results were similar between the ranibizu-
mab and aﬂibercept groups, consistent with previous evi-
dence comparing these agents.26 Higher rates of ocular
inﬂammation with aﬂibercept compared with ranibizumab
have been reported in previous communications,32,33 but
in the current study, no difference in ocular inﬂammation orRNF thickness was observed between the ranibizumab and
aﬂibercept groups.
The randomized, prospective design of the RIVAL study
is a strength, along with the identical treatment protocols
used for both drugs. The study used a CRC, ensuring con-
sistency in anatomic assessments. In addition, the masking
of the BCVA assessors and the CRC to treatment allocation
limits the bias in the results. Macular atrophy was assessed
using multimodal imaging, which is a best practice recom-
mendation,34 and was analyzed using square root
transformed data, which reduces the dependency of
atrophy growth on the size of atrophy at baseline.16
In terms of study limitations, the RIVAL study had a
discontinuation rate of 19.9% at 2 years, which is somewhat
higher than some other studies (e.g., 16% in VEGF Trap-
Eye: Investigation of Efﬁcacy and Safety in Wet Age-
Related Macular Degeneration and 14% in Inhibition of
VEGF in Age-Related Choroidal Neovascularization).6,26,27
In addition, longer follow-up might have provided greater
insights. At 2 years, the study period might have been too
short to observe effectively the development of new MA,
which is known to be a very slow process.
Natural history studies indicate that progression of MA
is relentless, although rates may differ at different stages
of the lesions, both incident and enlargement of estab-
lished MA.18 The hypothesis that anti-VEGF therapies
have a role in inﬂuencing rates of MA progression remains
controversial.3e13 The results from this study do not have
any bearing on the potential role of these agents in MA
progression. However, they do indicate that differing
modes of action in retinal suppression of VEGF, where
treatment exposure is virtually identical, does not seem to
inﬂuence rates of progression over 2 years. The high
proportion of patients who demonstrated MA over 2 years
in both the ranibizumab and the aﬂibercept groups indicate
that maintaining or at least stabilizing the VA gains that
are achieved with anti-VEGF agents remains a challenge.
Further studies are required to determine if this can be
altered by the use of anti-atrophy agents such as neuro-
trophic factors. It remains to be seen how much longer
longer-acting anti-VEGF agents will act. There is a po-
tential for a greater amount of MA when drugs have longer
half-lives. This should be studied when longer-acting
agents are introduced.
In conclusion, the RIVAL study found no statistical
difference between ranibizumab 0.5 mg and aﬂibercept 2.0
mg in the development of MA in nAMD patients treated
over 24 months. Ranibizumab and aﬂibercept achieved
similar visual acuities and retinal thickness improvements
over 24 months using a T&E regimen for nAMD, with
similar numbers of injections and comparable safety
results.
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